Your search returned 10 results.

Results
	1.	P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2- Metastatic Breast Cancer-A Podcast. MedStar authors: Gallagher, Christopher PMID: 37148492 Year: 2023 Citation: Targeted Oncology. 18(3):321-326, 2023 May. Institution: Washington Cancer Institute Medline publication type: Letter Observational Study Form of publication: Journal Article All authors: Brufsky A, Gallagher C DOI: https://dx.doi.org/10.1007/s11523-023-00968-4 Add to cart (remove)
	2.	P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2- Metastatic Breast Cancer-A Podcast. MedStar authors: Gallagher, Christopher PMID: 37148492 Year: 2023 Citation: Targeted Oncology. 18(3):321-326, 2023 May. Institution: Washington Cancer Institute Medline publication type: Letter Observational Study Form of publication: Journal Article All authors: Brufsky A, Gallagher C DOI: https://dx.doi.org/10.1007/s11523-023-00968-4 Add to cart (remove)
	3.	Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors: Swain, Sandra M PMID: 24129974 Year: 2013 Citation: Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM DOI: http://dx.doi.org/10.1007/s10549-013-2710-z Add to cart (remove)
	4.	Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors: Swain, Sandra M PMID: 24869931 Year: 2014 Citation: Oncologist. 19(7):693-701, 2014 Jul. Institution: Washington Cancer Institute Form of publication: Journal Article All authors: Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM DOI: http://dx.doi.org/10.1634/theoncologist.2014-0033 Add to cart (remove)
	5.	Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors: Swain, Sandra M PMID: 23868905 Year: 2013 Citation: Annals of Oncology. 24(10):2630-5, 2013 Oct. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM DOI: http://dx.doi.org/10.1093/annonc/mdt274 Add to cart (remove)
	6.	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors: Swain, Sandra M PMID: 23602601 Year: 2013 Citation: Lancet Oncology. 14(6):461-71, 2013 May. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM DOI: http://dx.doi.org/10.1016/S1470-2045(13)70130-X Add to cart (remove)
	7.	Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel. MedStar authors: Swain, Sandra M PMID: 23969513 Year: 2013 Citation: Anti-Cancer Drugs. 24(10):1084-92, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Journal Article Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Brewster M, Cortes J, Garg A, Grincuka E, Hauschild M, Kudaba I, Lum BL, Marier JF, Masuda N, McNally V, Nijem I, Patel T, Ross G, Swain SM, Trinh MM, Visich J DOI: http://dx.doi.org/10.1097/CAD.0000000000000016 Add to cart (remove)
	8.	Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors: Swain, Sandra M PMID: 27693116 Year: 2017 Citation: Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N DOI: https://dx.doi.org/10.1016/j.clbc.2016.07.008 Add to cart (remove)
	9.	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors: Swain, Sandra M PMID: 34890214 Year: 2022 Citation: Journal of Clinical Oncology. 40(5):438-448, 2022 02 10. Department: Associate Dean for Research Development Medline publication type: Journal Article Form of publication: Journal Article All authors: Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP DOI: https://dx.doi.org/10.1200/JCO.21.00896 Add to cart (remove)
	10.	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors: Swain, Sandra M PMID: 24095300 Year: 2013 Citation: Lancet Oncology. 14(12):1183-92, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N DOI: http://dx.doi.org/10.1016/S1470-2045(13)70411-X Add to cart (remove)

Powered by Koha